Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MCRB with free AI briefings, catalyst countdowns, and dilution alerts.

MCRB · Seres Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$17.5M Cash on Hand
3.2mo Cash Runway
Follow MCRB by email Get an email when MCRB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MCRB, unsubscribe in one click. Privacy

📣 What MCRB Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
SER-109 Clostridium Difficile Infection Phase 3 · NCT03183128 Completed
SER-287 Ulcerative Colitis Phase 2 · NCT03759041 Terminated
Vancomycin Pre-Treatment Ulcerative Colitis Phase 2 · NCT03759041 Terminated
Microbiome SER-155 Allogeneic Hematopoietic Stem Cell Transplantation Phase 1 · NCT04995653 Completed
SER-262 Clostridium Difficile Infection Phase 1 · NCT02830542 Completed
Microbiome SER-401 Metastatic Melanoma Phase 1 · NCT03817125 Completed
Vancomycin Pre-Treat Ulcerative Colitis Phase 1 · NCT02618187 Completed
Vancomycin pretreatment Metastatic Melanoma Phase 1 · NCT03817125 Completed

Also used in these trials (approved or third-party drugs, not MCRB's own candidates): Nivolumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MCRB holds $17.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $16.4M/quarter from operations, an estimated runway of 3.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 87 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MCRB files for a raise →

👥 Who Owns MCRB

Insiders 0.4% Institutions (53 holders) 22.2% Public and other holders 77.4%
HolderTypeShares% of sharesAs of
Eric D. Shaff
Director · +8,493 options
Insider 12,499 0.12% 2026-08-15
Kelly Brady
EVP, Chief Operating Officer · +19,298 options
Insider 8,679 0.09% 2026-08-15
Teresa L. Young
EVP, Chief Commercial & Strategy Officer · +780 options
Insider 8,557 0.08% 2026-02-15
Thomas DesRosier
EVP and Chief Legal Officer · +8,167 options
Insider 8,117 0.08% 2026-08-15
Matthew R Henn
President and Chief Scientific Officer · +25,585 options
Insider 7,995 0.08% 2026-08-15

Share count 10,195,031 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full MCRB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MCRB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.